https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49987 Wed 28 Feb 2024 16:27:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51451 3 seconds on CTP. Regression analyses were used to identify clinical and imaging variables that predicted poor functional outcome. Results: A total of 139 patients with mild stroke were included, of whom 27 (19%) had poor functional outcome. Patients with poor outcome, compared with those with good outcome, had much larger perfusion lesion volume (median 80 mL vs 41 mL, p < 0.001). Perfusion lesion was a significant predictor of poor outcome in either univariable regression (crude OR = 1.02, 95% CI = [1.01-1.03]) or multivariable regression model (adjusted OR = 1.01, 95% CI = [1.01-1.02]), adjusting for occlusion site, good collaterals, baseline stroke severity, age, IV thrombolysis (IVT), and onset to scan time. A perfusion lesion of 65 mL was the optimal cutpoint to identify poor functional outcome (sensitivity = 59%, specificity = 77%). Patients with perfusion lesion ≥65 mL, compared with patients with perfusion lesion <65 mL, showed a much higher rate of poor functional outcome (38% vs 11%, p < 0.001). Of the 139 patients in this study, 95 received IVT. Patients treated with or without IVT did not influence their outcomes (crude OR = 0.74, 95% CI = [0.31-1.78]). Discussion: A perfusion lesion of ≥65 mL predicted poor functional outcome in mild stroke patients with LVO.]]> Wed 28 Feb 2024 15:56:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45221 Wed 26 Oct 2022 14:53:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33380 Wed 24 Oct 2018 10:18:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52432 Wed 11 Oct 2023 14:47:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52413 Wed 11 Oct 2023 11:59:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50841 Wed 09 Aug 2023 09:10:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32035 Wed 06 Apr 2022 13:59:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30830 Wed 04 Sep 2019 09:56:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47794 Tue 31 Jan 2023 15:19:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54064 55%) and prognosis >12 months (based on disease-specific risk scores) were significantly associated with overall survival (P = 0.024 and P = 0.001). Induction and posttransplantation therapy were predictive of poor ICU survival outcome (P < 0.0001 and P = 0.041). APACHE scores were significant predictors of ICU mortality (P = 0.002 for APACHE II and P < 0.0001 for APACHE III). Conclusion: Survival outcomes for patients with hematological malignancy admitted to the ICU correlate with functional and comorbidity status. Disease-specific prognostic scores can assist in recognizing patients likely to benefit from ICU admission.]]> Tue 30 Jan 2024 13:58:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48115 Tue 28 Feb 2023 15:06:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52000 Tue 26 Sep 2023 11:29:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54240 Tue 13 Feb 2024 13:19:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54158 Tue 06 Feb 2024 12:17:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54155 Tue 06 Feb 2024 12:11:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51452 2) were modeled within purpose-built Bayesian linear and logistic regression frameworks. Interaction effects between stroke lesions and a high vs low WMH burden were integrated via hierarchical model structures. Models were adjusted for age, age2, sex, total DWI lesion and WMH volumes, and comorbidities. Data were split into derivation and validation cohorts. Results: A total of 928 patients with AIS contributed to acute stroke severity analyses (age: 64.8 [14.5] years, 40% women) and 698 patients to long-term functional outcome analyses (age: 65.9 [14.7] years, 41% women). Stroke severity was mainly explained by lesions focused on bilateral subcortical and left hemispherically pronounced cortical regions across patients with both a high and low WMH burden. Lesions centered on left-hemispheric insular, opercular, and inferior frontal regions and lesions affecting right-hemispheric temporoparietal regions had more pronounced effects on stroke severity in case of high compared with low WMH burden. Unfavorable outcomes were predominantly explained by lesions in bilateral subcortical regions. In difference to the lesion location–specific WMH effects on stroke severity, higher WMH burden increased the odds of unfavorable outcomes independent of lesion location. Discussion: Higher WMH burden may be associated with an increased stroke severity in case of stroke lesions involving left-hemispheric insular, opercular, and inferior frontal regions (potentially linked to language functions) and right-hemispheric temporoparietal regions (potentially linked to attention). Our findings suggest that patients with specific constellations of WMH burden and lesion locations may have greater benefits from acute recanalization treatments. Future clinical studies are warranted to systematically assess this assumption and guide more tailored treatment decisions.]]> Tue 05 Sep 2023 18:01:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51450 Tue 05 Sep 2023 17:56:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43821 +ß7⁺ gut-homing T cells appear to be linked to the pathophysiology of both FD and IBS. Studies in the area are complicated by poor phenotyping of patients into subgroups and the subtle nature of the immune activity involved in FD and IBS. CONCLUSIONS: Alterations in proportions of gut-homing T lymphocytes in both FD and IBS indicate that a loss of mucosal homeostasis may drive the symptoms of FD and IBS. There is indirect evidence that Th17 responses may play a role in FGIDs, however the evidence for a Th2 immune phenotype in FD and IBS is limited. Although immune involvement is evident, large, well-characterised patient cohorts are required to elucidate the immune mechanisms driving the development of FGIDs.]]> Tue 04 Oct 2022 10:29:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33600 Thu 22 Nov 2018 16:43:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49990 Thu 22 Jun 2023 14:05:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25845 Thu 17 Mar 2022 14:40:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46068 Thu 10 Nov 2022 14:23:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52222 Thu 05 Oct 2023 10:30:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50720 Thu 03 Aug 2023 09:33:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5178 g), a novel intronic change IVS1+36 g>c and two common variants A148T and IVS3+29 c>g. The results of this study revealed a paucity of mutations in CDKN2A/ARF suggesting that in the Polish population this gene does not contribute significantly to early-onset breast cancer, pancreatic cancer and malignant melanoma.]]> Sat 24 Mar 2018 07:47:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42367 Mon 22 Aug 2022 14:08:53 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46218 Mon 14 Nov 2022 12:12:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54760 Mon 11 Mar 2024 15:01:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54761 Mon 11 Mar 2024 15:00:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41051 p < 0.001). The relationship of core growth and CTP collateral index was validated in cohort 2. An increment in collateral index by 1% resulted in an increase of core growth by 0.59 mL/h (coefficient 0.59 [0.48–0.71], p < 0.001) in cohort 2. Conclusion: Collateral status is a major determinant of ischemic core growth.]]> Mon 08 Aug 2022 14:50:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54113 Mon 05 Feb 2024 10:02:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41260 Mon 01 Aug 2022 09:21:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48737 Fri 31 Mar 2023 16:23:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51230 15 mL/h) and slow (≤15 mL/h), based on its interaction with bridging IVT in predicting the primary outcome. The primary outcome was modified Rankin scale of 0-2 at 3 months. The secondary outcomes included successful thrombectomy reperfusion defined by modified Thrombolysis in Cerebral Infarction score of 2b-3 and time from groin puncture to reperfusion. Results: Of the 1,221 EVT patients in the INSPIRE, 323 patients were selected, of which 82 patients received direct EVT and 241 patients received bridging IVT. Bridging IVT was associated with a higher rate of good clinical outcome among patients with fast core growth (39% vs 7% for direct EVT, odds ratio [OR] 8.75 [1.96-39.1], p = 0.005), but the difference was not notable for patients with slow core growth (55% vs 55% for direct EVT, OR 1.00 [0.53-1.87], p = 0.989). In patients with fast core growth, the bridging and direct EVT patients showed no difference in the reperfusion rate (80% vs 76%, p = 0.616). However, patients who received bridging IVT were more likely to achieve reperfusion earlier (the median groin to reperfusion time of 63.0 vs 94.0 minutes, p = 0.005). Discussion: Patients with fast core growth were more likely to benefit from bridging IVT. This is likely because prior IVT facilitates clot removal and thus reduces time to reperfusion.]]> Fri 25 Aug 2023 13:18:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53112 Fri 17 Nov 2023 11:52:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53205 Fri 17 Nov 2023 11:34:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47319 70mL. We aimed to compare outcomes of EVT and non-EVT patients with an ischemic core≥70mL, hypothesizing that there would be a benefit from EVT for fair outcome (three-month modified Rankin Scale, mRS, 0-3) after stroke. METHODS: Retrospective analysis of patients enrolled into a multi-center (Australia, China and Canada) registry (2012-2020) who underwent CTP within 24 hours of stroke onset and had a baseline ischemic core≥70mL. Primary outcome was the estimation of the association of EVT in patients with core volume ≥70mL, as well as within 70-100mL and ≥100mL subgroups with fair outcome. RESULTS: Of the 3283 patients in the registry, 299 had CTP core≥70 mL and 269 complete data (135 had core volume between 70-100mL and 134≥100mL). EVT was performed in 121(45%) patients. EVT-treated patients were younger (median 69 versus 75 years; p=0.011), had lower pre-stroke mRS, and smaller median core volumes, 92[79-116.5]mL versus 105.5[85.75-138]mL, (p=0.004). EVT-treated patients had higher odds of achieving fair outcome in adjusted analysis (30% versus 13.9% in the non-EVT group; aOR 2.1(95% CI 1, 4.2), p=0.038). The benefit was seen predominantly in those with 70-100mL core (71 /135 (52.6%) EVT-treated), with 54.3% in EVT-treated versus 21% in non-EVT group achieving a fair outcome (aOR 2.5 (95% CI 1, 6.2), p=0.005). Of those with a core≥100mL, 50 /134(37.3%) underwent EVT. Proportions of fair outcome were very low in both groups (8.1% versus 8.7%; p=0.908). DISCUSSION: We found a positive association of EVT with 3-month outcome after stroke in patients with a baseline CTP ischemic core volume 70-100 mL but not in those with ≥100 mL. Randomized data to confirm these findings is required. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that EVT is associated with better motor outcomes 3 months following CTP-defined ischemic stroke with core of 70-100 mL.]]> Fri 13 Jan 2023 11:06:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49370 Fri 12 May 2023 13:38:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51539 Fri 08 Sep 2023 14:23:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44114 Fri 07 Oct 2022 14:05:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53506 Fri 01 Dec 2023 10:44:38 AEDT ]]>